PPT - Tyrosine Kinase Inhibitors in non-small cell lung cancer PowerPoint Presentation - ID:3372145
Dr. Giaccone on Treatment Options in NSCLC | Giuseppe Giaccone, MD, PhD, of Weill Cornell Medicine discusses current treatment options in non–small cell lung cancer. https://bit.ly/32ELJ2F | By OncLive | Facebook
Dr. Giaccone on Investigational Agents in Thymic Cancers
ITMIG 2017—Dr. Giuseppe Giaccone: focus on data and keep up-to-date - Huang - Mediastinum
Dr. Giuseppe Esposito, MD – Washington, DC | Nuclear Medicine
Loop | Giuseppe Giaccone
Frontiers in Oncology on X: "We are happy to announce that Wafik El-Deiry of Brown University (@BrownMedicine) is joining Giuseppe Giaccone as the new co-Chief Editor for our Cancer Molecular Targets and
Dr. Giuseppe Giaccone, MD – New York, NY | Oncology
Giuseppe Giaccone: Leading Clinical Oncology Research Expansion | Georgetown University Medical Center | Georgetown University
Dr. Giuseppe Giaccone | Mesothelioma Expert in New York
Dr. Giuseppe Giaccone, MD, PhD | New York, NY | Oncologist
ITMIG 2017# Interview with Dr. Giuseppe Giaccone: We should focus on data, and keep up-to-date - YouTube
Stephen V Liu, MD on X: "#ESMO20 Beppe Giaccone presents the phase 3 Atalante-1 trial of the vaccine OSE-2101 vs standard chemotherapy (docetaxel or pemetrexed) in patients with #NSCLC after immune checkpoint
Giuseppe Giaccone, PhD, MD, speculates on next steps in the development of Tedopi (OSE2101) - YouTube
Dr. Giuseppe Giaccone, MD, PhD | New York, NY | Oncologist
Loop | Giuseppe Giaccone
Loop | Giuseppe Giaccone
Giuseppe Giaccone, MD PhD, National Cancer Institute | Team Draft
Dr. Giuseppe Giaccone, MD: Hematologist - New York, NY - Medical News Today
The Road to Progress in Lung Cancer Treatment - The ASCO Post
Dr. Giuseppe Giaccone, MD – New York, NY | Oncology
Dr. Giaccone on Investigational Agents in Thymic Cancers
Giuseppe Giaccone, MD PhD, National Cancer Institute on Vimeo
Research in a Minute: Dr. Giuseppe Giaccone - YouTube
Loop | Giuseppe Giaccone
Author & co-authors
Hepatoid Carcinoma of the Lung with Anaplastic Lymphoma Kinase Gene Rearrangement Sean Khozin, MD, Mark J. Roth, MD, Arun Rajan, MD, Karen Smith, MD, - ppt download
Atezolizumab bests chemo in NSCLC patients with high PD-L1 expression | MDedge Hematology and Oncology
